Used as a key chiral intermediate in the synthesis of biologically active compounds, particularly in the development of pharmaceuticals. Its structure allows for selective introduction of the 2,6-difluorophenyl moiety in peptide-like frameworks, making it valuable in medicinal chemistry for designing protease inhibitors and other targeted therapies. The Fmoc group enables solid-phase peptide synthesis compatibility, allowing stepwise assembly of complex molecules under mild conditions. Commonly employed in research settings for creating analogs with improved metabolic stability and binding affinity.